Whistler

Nicox Updates on Corporate, Pipeline and Financing Perspectives and Will Hold a Webcast on March 18, 2024

Retrieved on: 
Wednesday, March 13, 2024
Mont Blanc, IOP, OCT, Whistler, Glaucoma, Ocular hypertension, Fluticasone, Database, Intraocular pressure, NCX, COVID-19, Patient, NDA, BlackRock, Sale, Bausch & Lomb, Therapy, Retina, Allergic conjunctivitis, Safety, Patent, Telecanthus, FDA, Corporation, Food, Pharmaceutical industry

“Nicox is focusing its resources on the Denali Phase 3 pivotal trial of its lead asset NCX 470 in glaucoma.

Key Points: 
  • “Nicox is focusing its resources on the Denali Phase 3 pivotal trial of its lead asset NCX 470 in glaucoma.
  • We are reducing costs, including the size of the organization, and are exploring advancing NCX 1728, through collaborations.
  • In January 2024, Nicox expanded the territory of the exclusive licensing agreement with Harrow, Inc., to include Canada.
  • The Company is financed to at least November 2024, based on focusing exclusively on the development of NCX 470.

Nicox Provides Fourth Quarter 2023 Financial and Business Highlights

Retrieved on: 
Thursday, January 25, 2024
Glaucoma, Patient, Bausch & Lomb, Marshal of France, NCX, Nitric oxide, Prescription, Ocular hypertension, IOP, COVID-19, Whistler, Intraocular pressure, Pharmaceutical industry

Net revenue €1.3 million for fourth quarter 2023 and €4.2 million for the full year 2023, an increase of 29% compared to the full year 2022

Key Points: 
  • Net revenue €1.3 million for fourth quarter 2023 and €4.2 million for the full year 2023, an increase of 29% compared to the full year 2022
    Cash of €11.9 million on December 31, 2023
    The Company is financed to June 2024, based on the development of NCX 470 alone, and continues to seek opportunities to increase the cash runway
    Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today provided financial and business highlights for the fourth quarter of 2023 for Nicox SA and its subsidiaries (the “Nicox Group”).
  • The Company remains focused on the financial situation and finding solutions to extend the cash runway.” said Andreas Segerros, Chief Executive Officer of Nicox.
  • In 2024 we are expecting approval and commercialization of ZERVIATE in China, which should further contribute to licensing revenue growth.”
    Net revenue1 for the fourth quarter of 2023 was €1.3 million, compared to €1.0 million of net revenue for the fourth quarter of 2022.
  • As of December 31, 2023, the Nicox Group had cash and cash equivalents of €11.9 million, compared with €14.6 million as of September 30, 2023 and €27.7 million as of December 31, 2022.

Nevada Canyon Announces Appointment of New Directors

Retrieved on: 
Thursday, January 18, 2024
Diamond, Diavik Diamond Mine, Architecture, Research, Regent's University London, Whistler, Larix laricina, Geology, STS, Bachelor of Science, Bemidji State University, Compensated emancipation, Smith, Engineering, Audit committee, DOD, California State University, Management

Reno, Nevada, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Nevada Canyon Gold Corp. (OTC Markets: NGLD) (the “Company” or “Nevada Canyon”) is pleased to announce the appointment of Mr. John Schaff, B.Sc.

Key Points: 
  • Reno, Nevada, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Nevada Canyon Gold Corp. (OTC Markets: NGLD) (the “Company” or “Nevada Canyon”) is pleased to announce the appointment of Mr. John Schaff, B.Sc.
  • as new independent directors to its Board of Directors, effective immediately.
  • With the appointment of these additional Directors, the Board is now comprised of five (5) directors, of which three (3) are considered independent.
  • “We’re excited to expand our board of directors with these new members who bring both a wealth of experience in Nevada and contacts to the Company,” said Jeffrey Cocks, Chairman of the Board of Directors of the Company.

Nicox Announces First Patient Screened in the Whistler Phase 3b Trial of NCX 470 in Glaucoma

Retrieved on: 
Monday, December 18, 2023
IOP, Blood, Whistler, Glaucoma, NCX, Intraocular pressure, Ocular hypertension, Mayo Clinic, Bimatoprost, Nitric oxide, Patient, EVP, Clinical professor, Humour, Pharmaceutical industry

Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that the first patient has been screened in the Whistler Phase 3b clinical trial investigating the dual mechanism of action (nitric oxide and prostaglandin analog) of NCX 470 in intraocular pressure (IOP) lowering.

Key Points: 
  • Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that the first patient has been screened in the Whistler Phase 3b clinical trial investigating the dual mechanism of action (nitric oxide and prostaglandin analog) of NCX 470 in intraocular pressure (IOP) lowering.
  • NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop, is our lead product candidate in Phase 3 clinical development for IOP lowering in patients with open-angle glaucoma or ocular hypertension.
  • Each subject will participate in the trial for ~8 days and will provide insight into the mechanism of action of NCX 470.
  • The Company is currently funded until the end of June 2024, exclusively on the basis of the development of NCX 470.

Monster Energy's UNLEASHED Podcast Welcomes Team USA Snowboarder and Triple-Threat Extraordinaire Judd Henkes

Retrieved on: 
Tuesday, December 12, 2023
Team, Fortnight, Spotify, Pressure, DNA, Monster Energy, Life, United States national team, Winter Olympic Games, Snow, ITunes, Studio, Energy, Season, Music, Whistler, UFC, Silver, Winter, CORONA, Fuel TV, Family, Athlete, Sport, Radio Studio M, Sand, Mammoth Mountain, Sports equipment, Film industry, Entertainment, Nightclub, Dingo, Half-pipe, Greenhorn, Henkes

CORONA, Calif., Dec. 12, 2023 /PRNewswire-PRWeb/ -- How about a pro snowboarder who could also be a sponsored surfer? Monster Energy is proud to welcome multi-talented snowboarder, surfer, and skateboarder Judd Henkes on Episode 326 of the sports and pop culture podcast UNLEASHED with The Dingo, Danny, and Brittney.

Key Points: 
  • Monster Energy is proud to welcome multi-talented snowboarder, surfer, and skateboarder Judd Henkes on Episode 326 of the sports and pop culture podcast UNLEASHED with The Dingo, Danny, and Brittney.
  • Monster Energy is proud to welcome multi-talented snowboarder, surfer, and skateboarder Judd Henkes on Episode 326 of the sports and pop culture podcast UNLEASHED with The Dingo, Danny, and Brittney.
  • Visit the landing page to access Episode 326 of UNLEASHED with The Dingo, Danny, and Brittney featuring Team USA snowboarder Judd Henkes .
  • The UNLEASHED with The Dingo, Danny, and Brittney Podcast is here to celebrate the personalities behind the Monster Energy lifestyle.

Nicox Provides First Half 2023 and Third Quarter 2023 Financial Results and Updates Key Milestones

Retrieved on: 
Friday, October 20, 2023
Mont Blanc, Intraocular pressure, Ocular hypertension, IOP, Nitric oxide, Acquisition, Glaucoma, NCX, Euronext Paris, Marshal of France, COVID-19, Whistler, Bausch & Lomb, Patient, ZTF J1813+4251, Music, Pharmaceutical industry, Cryptocurrency

Cash of €14.6 million on September 30, 2023

Key Points: 
  • Cash of €14.6 million on September 30, 2023
    Nicox SA (Euronext Paris: FR0013018124, ALCOX), an international ophthalmology company, today provided financial results for Nicox SA and its subsidiaries (the “Nicox Group”) for the first half of 2023 and for the third quarter of 2023 and provided an update on key future milestones.
  • Operating expenses for the first half of 2023 were €10.4 million compared to €12.7 million for the first half of 2022.
  • Net revenue for the third quarter of 2023 was €1.1 million (entirely composed of net royalty payments).
  • VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% U.S. prescriptions3 increased by 22% in the third quarter of 2023 compared to the same period in 2022.

National Police Federation Benevolent Foundation Announces NPFBF Bursary Program 2023 Recipients

Retrieved on: 
Thursday, September 7, 2023
Atlantic Central Football Conference, Bursary, Music, Education, MB, AB, Child, Student, Saanichton, Royal Canadian Mounted Police, Prince George, Grande Prairie, Sport, NPF, Spouse, Opaskwayak Cree Nation, N.B, Beausejour, RCMP, Nursing, Whistler, Saint Albert, Parkland County

OTTAWA, ON, Sept. 7, 2023 /CNW/ - The National Police Federation Benevolent Foundation (NPFBF) is pleased to announce the 2023 recipients of the 17 NPFBF bursaries awarded annually, providing financial assistance to post-secondary students including 13 members of the public, one child of an RCMP Member, and three RCMP Member spouses.

Key Points: 
  • OTTAWA, ON, Sept. 7, 2023 /CNW/ - The National Police Federation Benevolent Foundation (NPFBF) is pleased to announce the 2023 recipients of the 17 NPFBF bursaries awarded annually, providing financial assistance to post-secondary students including 13 members of the public, one child of an RCMP Member, and three RCMP Member spouses.
  • "Paying it forward through bursaries that support public safety higher education for eligible students across Canada both supports students and honours the memories of our Fallen Members," said Kevin Halwa, Chair of the National Police Federation Benevolent Foundation.
  • In total, the NPFBF Bursary Program distributes $47,500 annually to eligible students across Canada.
  • Below is a list of 2023 bursary recipients, by category:
    Atlantic/Central: Lauren Blakely (Waasis, N.B.

ALASKA GOVERNOR MIKE DUNLEAVY VISITS WHISTLER GOLD-COPPER PROJECT AND U.S. GOLDMINING PROVIDES UPDATE ON PROPOSED ACCESS ROAD

Retrieved on: 
Tuesday, August 8, 2023
Workforce, Alaska Department of Transportation & Public Facilities, State, IPO, Tri-Cities, DOT&PF, Resource, Policy, Susitna River, Transport, WSAR, Natural Resources, Industrialisation, DOT, USGO, PF, Goldmining project at Mount Ida region, Mining, Tunnel, Whistler

ANCHORAGE, Alaska, Aug. 8, 2023 /PRNewswire/ - U.S. GoldMining Inc. (NASDAQ: USGO) ("U.S. GoldMining" or the "Company") is pleased to provide details on Alaska State Governor Mike Dunleavy's recent visit to the Company's Whistler gold-copper project ("Whistler") in Alaska, USA.

Key Points: 
  • ANCHORAGE, Alaska, Aug. 8, 2023 /PRNewswire/ - U.S. GoldMining Inc. (NASDAQ: USGO) ("U.S. GoldMining" or the "Company") is pleased to provide details on Alaska State Governor Mike Dunleavy's recent visit to the Company's Whistler gold-copper project ("Whistler") in Alaska, USA.
  • The Company is also pleased to provide updates on recent significant advancements in Alaska State's 'Roads to Resources' initiative which includes the proposed West Susitna Access Road ("WSAR") to the Whistler project.
  • Alaska State Governor Mike Dunleavy and Alaska Department of Transportation and Public Facilities ("DOT&PF") Commissioner, Ryan Anderson, visited the Company's Whistler Project on August 3, 2023, accompanied by U.S. GoldMining's CEO, Tim Smith.
  • U.S. GoldMining looks forward to working with all governments, agencies and stakeholders as we advance the exciting Whistler gold-copper project".

Nicox Provides Second Quarter 2023 Financial and Business Highlights

Retrieved on: 
Wednesday, July 19, 2023
Mont Blanc, NCX, Retina, Latanoprost, Priority review, IOP, COVID-19, Whistler, Nitric oxide, Ophthalmology, Intraocular pressure, Bausch & Lomb, Glaucoma, Ocular hypertension, Euronext Paris, Patient, Marshal of France, News, Cryptocurrency, Pharmaceutical industry

Cash position of €19.0 million, with a 12-month cash runway, as of June 30, 2023

Key Points: 
  • Cash position of €19.0 million, with a 12-month cash runway, as of June 30, 2023
    Nicox SA (Euronext Paris: FR0013018124, ALCOX), an international ophthalmology company, today provided financial and business highlights for the second quarter 2023 for Nicox SA and its subsidiaries (the “Nicox Group”).
  • We look forward to the expected launch of this in 2024, bringing an additional revenue stream to Nicox.
  • VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% U.S. prescriptions3 increased by 26.2% in the second quarter of 2023 compared to the same period in 2022.
  • Laboratorios Grin, Nicox’s exclusive partner for ZERVIATE™ (cetirizine ophthalmic solution), 0.24% in Mexico, has provided notice to Nicox of the termination of this agreement, effective July 23, 2023.

U.S. GOLDMINING MOBILIZES FIELD TEAMS TO EXECUTE ON 2023 EXPLORATION PROGRAM AT WHISTLER GOLD-COPPER PROJECT, ALASKA

Retrieved on: 
Tuesday, May 30, 2023
Social responsibility, IPO, Rehabilitation, Equity, USGO, Investment, Natural Resources, Goldmining project at Mount Ida region, Alaska Department of Natural Resources, Renewable energy, Mining, Whistler

The Company has started executing its plans to unlock the value of the Company's Whistler gold-copper project ("Whistler") in Alaska, USA and has mobilized field teams to commence exploration activities.

Key Points: 
  • The Company has started executing its plans to unlock the value of the Company's Whistler gold-copper project ("Whistler") in Alaska, USA and has mobilized field teams to commence exploration activities.
  • The Company's board of directors has approved a budget to commence and execute Phase 1 of a two-year exploration program, including core drilling of up to 10,000 meters at the Whistler project.
  • Tim Smith, Chief Executive Officer of U.S. GoldMining, commented: "US GoldMining is now fully funded and permitted to start our inaugural exploration program at Whistler.
  • The Company has appointed Equity Exploration Consultants Ltd. ("Equity Exploration") to manage the geological and exploration functions at Whistler, including the planned drilling program.